分子检测已成为非小细胞肺癌治疗中更常见的必需品。使用下一代测序，可以用少量的核材料识别多个治疗靶点。作者评估了机器人辅助支气管镜在获取符合 PD-L1 免疫组织化学和/或下一代测序分析前标准的组织方面的性能。对通过机器人支气管镜诊断为原发性肺癌的患者进行了回顾性审查。对病理报告的分子检测结果和程序性死亡配体 1 (PD-L1) 检测进行了评估。独立病理学家评估了每种样本类型（涂片、细胞块、组织活检和/或接触准备），以确定每种组织类型是否符合尝试下一代测序和/或 PD-L1 免疫组织化学的预分析标准。 70-对八名原发性肺患者进行了检查。通过对细胞学涂片、细胞块、活检和/或接触准备的独立病理评估，发现 72% 的样本足以进行分子和 PD-L1 检测。根据样本类型确定下一代测序 (NGS) 和 PD-L1 染色的分析前充分性 (%)：NGS 细胞学涂片 48.6%； NGS 细胞块为 14.3%，PD-L1 细胞块为 32.9%；活检 NGS 为 29.2%，PD-L1 为 62.5%； 61.4% 的 NGS 接触准备。机器人辅助支气管镜检查产生的样本在 72% 的病例中符合分子检测的分析前标准。这些结果支持使用机器人辅助支气管镜对早期肺癌进行诊断和分子检测。版权所有 © 2023 作者。由爱思唯尔公司出版。保留所有权利。

Molecular testing has become a more frequent necessity in NSCLC management. Using next-generation sequencing, multiple targets for therapy can be identified with small amounts of nuclear material. The authors evaluated the performance of robotic-assisted bronchoscopy in acquiring tissue that meets pre-analytic criteria for PD-L1 immunohistochemistry and/or next-generation sequencing.Patients with a diagnosis of primary lung cancer identified through robotic bronchoscopy were retrospectively reviewed. Pathology reports were assessed for results of molecular testing and detection of programmed death-ligand 1 (PD-L1). An independent pathologist evaluated each specimen type (smears, cell block, tissue biopsy, and/or touch prep) to determine whether each tissue type would meet pre-analytic criteria for attempting next-generation sequencing and/or PD-L1 immunohistochemistry.Seventy-eight patients with primary lung were reviewed. By independent pathologic assessment of cytological smears, cell block, biopsy, and/or touch preparations, 72% of samples were found to be adequate for molecular and PD-L1 testing. Preanalytic adequacy (%) for next-generation sequencing (NGS) and PD-L1 staining was determined based on specimen type: cytological smear 48.6% for NGS; cell block 14.3% for NGS and 32.9% for PD-L1; biopsy 29.2% for NGS and 62.5% for PD-L1; and touch prep 61.4% for NGS.Robotic-assisted bronchoscopy yielded samples that met preanalytic criteria for molecular testing in 72% of cases. These results support the use of robotic-assisted bronchoscopy for both the diagnosis and molecular testing of early-stage lung cancer.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.